BEAT BioTherapeutics Corporation (BEATBio) announced today that there will be two scientific presentations related to its BB-R12 drug candidate for heart failure at the American Heart Association’s annual Scientific Sessions meeting in Chicago, IL. The BB-R12 gene therapy is based on the fundamental discovery that 2-Deoxy Adenosine Triphosphate (dATP) is a superior fuel for cardiac muscle contraction than is ATP. BB-R12 is being developed to treat heart failure by increasing cardiac dATP levels and cardiac muscle performance, allowing the heart to pump blood more effectively.
Help employers find you! Check out all the jobs and post your resume.
